Need Help?

Global Anaplastic Thyroid Cancer Initiative

Thyroid cancer is the most common endocrine malignancy. Most thyroid cancers are of the well-differentiated (non-aggressive) phenotype, and are almost always cured with standard treatments. In contrast, anaplastic thyroid cancer (ATC) is rare, accounting for only 1% of thyroid cancers, however it is perhaps the most lethal human malignancy with an average survival of 3 to 6 months. ATC presents with dramatic and rapid onset of airway and esophageal blockage with frequent spread to the lungs. Interestingly, 21–79% of ATCs have coexisting areas or a previous history of well-differentiated cancers. Although this suggests a progression from well-differentiated cancers to ATC, to date there is little molecular conformation that such a progression exists versus de novo generation of ATC. As ATC is extremely rare and most cases are inoperable, there are a paucity of tissue samples for study at any one center. The Global Anaplastic Thyroid Cancer Initiative (GATCI) aims to unite international institutions in order to pool samples (ATC with or without a paired well-differentiated component) for a comprehensive analysis of the genomic landscape of this disease.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001003235 unspecified 172
EGAD00001003236 HiSeq X Ten 10
EGAD00001004126 -
EGAD00001004127 -
EGAD00001004128 -
EGAD00001004129 -
EGAD00001005791 -
EGAD00001005808 unspecified -
EGAD00001005810 unspecified 8
EGAD00001005817 -
EGAD00001005818 -
EGAD00001005822 -
EGAD00001005914 -
EGAD00001005916 -
EGAD00001005917 -
EGAD00001005918 -
EGAD00001005926 HiSeq X Ten unspecified -
EGAD00010001579 Oncoscan Array 157
Publications Citations
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
Cell Rep 43: 2024 113826